Terumo Corporation
IFRS Financial Results for the Third Quarter ofthe Fiscal Year Ending March 31, 2019

1IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2019
February 7, 2019
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Shinjiro Sato, President and CEO: Atsuo Omagari, General Manager, Corporate Communication Dept.
: +81 / 3-6742-8550

Company code number
Representative:
Please address all communications toPhone

1. Consolidated Financial Highlights for the Nine Months Ended December 31, 2018
(From April 1, 2018 to December 31, 2018)(1) Consolidated operating results(Notes: The amounts shown below ignore values of less than a million yen)

Revenue

Operating profit

Profit before tax(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

(Millions of yen)443,609436,955

1.5－

78,47486,569(9.4)－

75,00885,638(12.4)－

56,39576,907

Nine months ended December, 2018
Nine months ended December, 2017

Profit for the period
attributable to theowners of the parent

Profit for the period

Total comprehensiveincome for the period% (Millions of yen)%(Millions of yen)%

56,49576,974(26.6)－76,119
91,096(16.4)－(26.7)－Earnings per share,
fully diluted

Earnings per share
(Yen)

(Yen)

Nine months ended December, 2018155.33Nine months ended December, 2017
218.68(Notes)Adjusted operating profit: December 2018: 91,179million yen

149.20204.10December 2017: 97,571 million yen(2) Consolidated financial position
Total assets

As of December 31, 2018
As of March 31, 2018

Equity attributable to theowners of the parent

Net assetsEquity attributable to theowners of the parent ratio(Millions of yen)

(Millions of yen)

(Millions of yen)%

1,129,826
1,078,981

672,356
550,435

672,250
550,30759.5
51.0

2. Dividends
Cash dividends per share
1st quarter2nd quarter3rd quarter

4th quarter

Total

(Yen)

(Yen)

(Yen)

(Yen)

(Yen)

－

23.00
27.00

－

27.00

50.00

27.00

54.00

Year ended March, 2018Year ended March, 2019Year ending March, 2019 (forecast)(Notes) Revise of dividends forecast : None－－

3. Consolidated Forecast for the Year Ending March, 2019 (From April 1, 2018 to March 31, 2019)

Revenue(Millions of yen)

Adjusted operating profit%(Millions of yen)%

Profit for the year
attributable to the ownersof the parent

Operating profit(Millions of yen)

Earnings per share%(Millions of yen)

%

(Yen)

Year ending March, 2019
597,000
1.6
122,000(2.3)
108,000(0.5)(Notes) 1)Revise of forecast for fiscal year ending March, 2019 : None
Assumed exchange rate for the fourth quarter of the fiscal year ending March 31, 2019: USD1=JPY105, EUR1=JPY1302)Earnings per share is calculated by taking consideration effects of the conversion of convertible bond in the nine months.

78,500(14.0)

214.80Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based onlimited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results
include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

24. Consolidated Financial Statements① Consolidated Statements of Financial Position
As ofMarch 31, 2018

（Unit: Millions of yen）
As ofDecember 31, 2018

AssetsCurrent assets
Cash and cash equivalents

167,832

161,063

Trade and other receivables

121,402125,768

Other current financial assets

659

408

112,064

130,878

Current tax assets

530

564

Other current assets

8,421

10,806

Total current assets

410,912429,490

Property, plant and equipment

179,196

187,048

Goodwill and intangible assets

442,660467,257

Inventories

Non-current assets

Investments accounted for using the equity
methodOther non-current financial assets

5,710

5,651

13,815

14,828Deferred tax assets

23,35622,287

Other non-current assets

3,328

3,262

Total non-current assets

668,068

700,336

1,078,981

1,129,826

Total assets3

（Unit: Millions of yen）
As of
December 31, 2018

As ofMarch 31, 2018
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

67,51570,085

Bonds and borrowings

47,43649,455407

11,572

15,9705,750198180

Other current liabilities

47,48345,151

Total current liabilities

179,013

182,196

Bonds and borrowings

288,776

226,247

Other non-current financial liabilities

15,452

4,709

Deferred tax liabilities

24,124

23,779Defined benefit liabilities

10,063

9,147

82

87

Other non-current liabilities

11,032

11,301

Total non-current liabilities

349,532

275,274

528,545457,470

Share capital

38,716

38,716

Capital surplus

52,44552,044

Treasury stock(101,546)(35,281)

Retained earnings

588,932

625,229

Other components of equity(28,240)(8,458)550,307672,250128106

550,435

672,356

1,078,981

1,129,826

Other current financial liabilities
Current tax liabilities
Provisions

Non-current liabilities

Provisions

Total liabilities
EquityTotal equity attributable to the owners of theparent
Non-controlling interests
Total equity
Total liabilities and equity

4

② Consolidated Statements of Profit or Loss
For the nine months ended
December 31, 2017
436,955
198,305
238,649
154,103
3,316
1,293
86,569931
1,611（Unit: Millions of yen）
For the nine months endedDecember 31, 2018443,609
201,450
242,159
168,0376,629
2,277
78,474
1,621
4,985

(250)

(101)

85,638
8,731
76,90775,00818,61356,395Attributable to:
Owners of the parent
Non-controlling interests
Total profit for the period

76,974(67)
76,90756,495(100)
56,395

Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)218.68204.10155.33149.20

Revenue
Cost of sales
Gross profit
Selling, general and administrative expenses
Other income
Other expenses
Operating profit
Finance income
Finance costs
Share of profit (loss) of investments accounted
for using the equity method
Profit before tax
Income tax expenses
Profit for the period

5③ Consolidated Statements of Comprehensive Income

Profit for the period

For the nine months ended
December 31, 2017
76,907（Unit: Millions of yen）
For the nine months ended
December 31, 2018
56,395

714

(433)

(918)

－(204)(433)

14,01520,475

(58)

(258)

435

(58)

1－

14,393

20,15814,18919,72491,096

76,11991,16976,224

(72)

(104)

91,096

76,119Other comprehensive income
Items that will not be reclassified to profit or loss
Changes in financial assets measured at fairvalue through other comprehensive income
Remeasurement of difined benefit plan
Total items that will not be reclassified to profit
or loss
Items that are or may be reclassified subsequently
to profit or loss
Exchange differences on translation of foreign
operations
Cash flow hedges
Cost of hedging
Share of other comprehensive income/(loss) ofinvestments accounted for using the equity
methodTotal items that are or may be reclassified
subsequently to profit or loss
Other comprehensive income/(loss) for the periodTotal comprehensive income for the period
Attributable toOwners of the parent
Non-controlling interests
Total comprehensive income for the period(Note)

Items in the above statement are net of tax.

6

④ Consolidated Statements of Changes in Equity（Unit: Millions of yen）
Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents ofsurplus
stock
earnings
equitySharecapitalBalance at April 1, 2017

Noncontrollinginterests

Total

Total equity

38,71652,478(108,225)

513,578(5,126)

491,421101

491,522

Profit for the period－－－

76,974－

76,974(67)

76,907

Other comprehensive income

－－

－

－

14,194

14,194(5)

14,189Total comprehensive income
Acquisition of treasury shares－－－

76,974

14,194

91,169(72)

91,096

－

－

(4)

－－

(4)

－

(4)

Disposal of treasury shares

－

－

75

(5)

(69)

0

－

0

Dividends－－－(15,839)－(15,839)－(15,839)

－

－

－

(922)

922

－

－

－

－

－

－

－

－

－

136

136

－

－

－

－

447

447

－

447

－

－

71

(16,767)

1,299(15,396)136(15,259)

38,71652,478(108,154)

573,785

10,368567,194165

567,360

Transfer from other components ofequity to retained earnings
Change in shares of subsidiaries
due to capital increase
Share-based payments
Total transactions with the ownersof the Company
Balance at December 31, 2017

（Unit: Millions of yen）
Share
capitalBalance at April 1, 2018
Change of the accounting principles
Balance after the adjustment

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents ofsurplus
stock
earnings
equity52,445

Noncontrollinginterests

Total

Total equity(101,546)

588,932(28,240)

550,307128

550,435－54－

54(28,240)

550,361128

550,490

－

－

－

54

38,71652,445(101,546)

588,986

Profit for the period

－

－

－

56,495－56,495(100)

56,395

Other comprehensive income

－－

－

－

19,72819,728(4)

19,724

Total comprehensive income
Acquisition of treasury shares－－－

56,495

19,72876,224(104)

76,119

－

－

(6)

－

－

(6)

－

(6)

Disposal of treasury shares

－

－

155

(47)

(107)

0－

0

Dividends－－－(19,555)－(19,555)－(19,555)

－－－

1

(1)

－－－－－－－－－81

81

Transfer from other components ofequity to retained earnings
Change in shares of subsidiaries due
to capital increase
Share-based payments
Conversion of convertible bonds
Total transactions with the owners ofthe Company
Balance at December 31, 2018

－－－

－

162

162

－

162

－

(401)

66,116(650)－

65,064－65,064－(401)

66,264(20,252)53

45,66481

45,746

38,71652,044(35,281)625,229(8,458)672,250106672,356

7

5. Segment information
Reporting segment information
Revenue and operating results of the reporting segments of the Group are described below.
For the nine months ended December 31, 2017
（Unit: Millions of yen）

Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operatingprofit)（Adjustment item）
Amortization ofintangible assets
acquired throughbusiness combinations
Non-recurring profit orloss

Adjustments（Note）

Amountrecorded on
consolidated
financialstatements

CardiacandVascularCompany

GeneralHospitalCompany

Blood
Management
Company

240,038

120,231

76,510436,780174

436,955

63,352

21,168

12,21596,736835

97,571(4,227)－(6,280)(10,507)－(10,507)

Total(494)Operating profit

86,569Finance income

931

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
method

(1,611)Pre-tax profit

85,638(250)(Note） Amounts in ‘Adjustments’ are as follows:(1) ¥174 million adjustment to revenue from sales to external customers is mainly proceeds from outward
temporary staffing that is not attributable to reportable segments.
(2) ¥835 million adjustment to segment profit consists of ¥ 183 million for “inventories” and ¥651 million for“others”.

8For the nine months ended December 31, 2018（Unit: Millions of yen）
AmountrecordedonAdjustments
consolidated(Note）
financialstatements

Reportable Segments

Revenue
Revenue from sales
to external customers
Segment Profit(Adjusted operatingprofit)（Adjustment item）
Amortization of
intangible assets
acquired throughbusiness combinations
Non-recurring profit orloss

Cardiac andVascularCompany

GeneralHospitalCompany

Blood
Management
Company

240,957

125,869

76,591

443,418

190

443,60958,01522,328

10,89591,240(60)

91,179(4,839)－(6,294)(11,134)

99(11,034)

Total(1,670)

Operating profit

78,474

Finance income1,621

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
method(4,985)Pre-tax profit

75,008(101)(Note）１．Amounts in ‘Adjustments’ are as follows:(1) ¥190 million adjustment to revenue from sales to external customers is mainly proceeds from outward
temporary staffing that is not attributable to reportable segments.
(2) ¥(60) million adjustment to segment profit consists of ¥(874) million for “inventories” and ¥813 million for“others”.
２．¥(1,670) million Non-recurring profit or loss mainly includes ¥1,111 million insurance revenue about
hurricane in Puerto Rico and ¥(2,039) million for the change in fair value of contingent consideration related toacquisition of Sequent Medical, Inc..

〈Material subsequent events〉
Terumo Corporation (TSE: 4543) announced that its Board of Directors has decided a two-for-one stock split and anincrease from 1.519 billion to 3.038 billion in the number of authorized shares of the Company's common stock on
February 7, 2019. On April 1, 2019, each shareholder of record at the close on March 31, 2019 will receive one additional
share of common stock for every outstanding share of common stock held.

9